Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function

Movement Disorders

Volumn 28, Issue 2, 2013, Pages 153-160

  Macdonald, Alex A ^a   Monchi, Oury ^b,c   Seergobin, Ken N ^d   Ganjavi, Hooman ^e   Tamjeedi, Ruzbeh ^a   Macdonald, Penny A ^e  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE DE RECHERCHE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Basal ganglia; Cognition; Dopamine; Parkinson's disease; Striatum

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; LEARNING; PARKINSON DISEASE; PRIORITY JOURNAL; REWARD; STIMULUS RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL STIMULATION;

AGE FACTORS; AGE OF ONSET; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BASAL GANGLIA; COMPUTERS; DOPAMINE; DOPAMINE AGENTS; EDUCATIONAL STATUS; FEMALE; HUMANS; LEARNING; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PHOTIC STIMULATION; PSYCHOMOTOR PERFORMANCE; REWARD;

EID: 84874203590     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25152     Document Type: Article

References (32)

1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
2. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23.
3. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988;111:299-321.
4. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl J Med 1988;318:876-880.
5. Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003;26:317-330.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455.
7. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
8. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain, and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 1999;122:1637-1650.
9. Shahed J, Jankovic J. Motor symptoms in Parkinson's disease. Handb Clin Neurol 2007;83:329-342.
10. Hornykiewicz O. The mechanisms of action of L-dopa in Parkinson's disease. Life Sci 1974;15:1249-1259.
11. Macdonald PA, Monchi O. Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson's disease: implications for cognitive function. Parkinsons Dis 2011;2011:572743.
12. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
13. Graef S, Biele G, Krugel LK, et al. Differential influence of levodopa on reward-based learning in Parkinson's disease. Front Hum Neurosci 2010;4:169.
14. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003;41:1431-1441.
15. Frank MJ. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated parkinsonism. J Cognitive Neurosci 2005;17:51-72.
16. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004;306:1940-1943.
17. Shohamy D, Myers CE, Grossman S, Sage J, Gluck MA. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease. Behav Brain Res 2005;156:191-199.
18. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38:596-612.
19. Macdonald PA, Macdonald AA, Seergobin KN, et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 2011;134:1447-1463.
20. Cools R, Lewis SJG, Clark L, Barker RA, Robbins TW. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-189.
21. Gotham AM, Brown RG, Marsden CD. Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease. Lancet 1986;2:970-971.
22. Cools R, Clark L, Owen AM, Robbins TW. Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 2002;22:4563-4567.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
24. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45-53.
25. Declaration of Helsinki. Law Med Health Care 1991;19:264-265.
26. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
27. Macdonald PA, Macdonald AA, Seergobin KN, et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. Brain 2011;134:1447-1463.
28. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
29. Wickens JR, Budd CS, Hyland BI, Arbuthnott GW. Striatal contributions to reward and decision making: making sense of regional variations in a reiterated processing matrix. Ann N Y Acad Sci 2007;1104:192-212.
30. Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J Neurosci 2009;29:4035-4043.
31. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.
32. Borroni B, Turla M, Bertasi V, Agosti C, Gilberti N, Padovani A. Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. Arch Gerontol Geriatr 2008;47:53-61.